Solutions & Models

While the barriers to psychedelic therapy implementation are real, so are the solutions being developed to overcome them. Across the field, researchers, clinicians, entrepreneurs, and policymakers are designing innovative approaches to make these therapies deliverable, affordable, and scalable.

On the delivery side, group therapy models are emerging as one of the most promising innovations. Rather than one-on-one sessions, some protocols are exploring guided group experiences with multiple patients and fewer therapists per session. Early evidence from group psilocybin sessions suggests that therapeutic outcomes may be comparable to individual sessions, while dramatically reducing the per-patient cost. If validated in larger trials, group models could fundamentally change the economics of psychedelic therapy.

Training and certification programs are evolving rapidly. Organizations like MAPS, the Integrative Psychiatry Institute, and several university programs are developing standardized training curricula. Some jurisdictions are creating formal certification requirements — Oregon's Psilocybin Services Act, for example, established a state-level training and licensing framework. The challenge is balancing thoroughness with speed: the field needs well-trained therapists, but it also needs enough of them to meet demand.

Technology is playing an increasingly important role. Digital therapeutics platforms are being developed to support preparation and integration phases, potentially reducing the therapist time required per patient. Telemedicine integration could extend access to rural and underserved areas. And data platforms (like Blossom) are helping researchers, policymakers, and clinicians navigate the rapidly growing evidence base.

Policy innovation is also accelerating. From Oregon and Colorado's state-level frameworks to Australia's rescheduling decision, jurisdictions around the world are experimenting with different regulatory and delivery models. These early experiments will generate crucial real-world evidence about what works — and what doesn't — in practice. In this section, we highlight the most promising solutions and models, examine the evidence behind them, and consider how they might scale across different healthcare systems.